Purging of autografts: Methods and clinical significance

Annals of Medicine

Volumn 28, Issue 2, 1996, Pages 167-173

  Kvalheim, Gunnar ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Autografts; Clinical significance; Purging

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALKYLLYSOPHOSPHOLIPID; BLEOMYCIN; CYTOTOXIC AGENT; ETOPOSIDE; IMMUNOTOXIN; MAFOSFAMIDE;

AUTOGRAFT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HEMATOPOIETIC STEM CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0029924615     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899609092942     Document Type: Review

References (67)

1. Gianni A, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-4.
2. Haas R, Mohle R, Fruehauf S, et al. Patients' characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells (PBPC) in malignant lymphoma. Blood 1994; 83: 3787-94.
3. Bensinger W, Abbelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-55.
4. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplantations for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-96.
5. Vose J, Armitage JO. Clinical application of hematopoietic growth factors. Blood 1995; 13: 1023-35.
6. Eaves, CJ. Peripheral blood stem cells reach new heights. Blood 1993; 82: 1957-9.
7. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 28: 1525-33.
8. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-6.
9. Deisseroth A, Zu Z, Claxton D, et al. Genetic marking shows that Ph+cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-76.
10. Moss TJ, Ross AA. The risk of tumour cell contamination in peripheral blood stem cell collections. J Hematother 1992; 1: 225-32.
11. Moss TJ, Sanders DG, Lasky LC, Bostrom B. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990; 76: 1879-83.
12. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumour cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-10.
13. Pantel K, Felber E, Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother 1994; 3: 315-22.
14. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumour cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992; 10: 1534-9.
15. Shpall EJ, Jones R B. Release of tumour cells from bone marrow. Blood 1994; 83: 623-35.
16. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumour cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumours. Blood 1994; 83: 636-40.
17. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-57.
18. Negrin RS, Pesando J. Detection of tumour cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations. J Clin Oncol 1994; 12: 1021-7.
19. Corradini P, Voena C, Astoifi M, et al. High dose sequential chemotheray in multiple myeloma: residual tumour cells are detectable in bone marrow and peripheral blood cell harvest and after autografting. Blood 1995; 85: 1596-602.
20. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth M S. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475-82.
21. Sharp JG, Mann SL, Murphy B, Weekes C. Culture methods for the detection of minimal tumour contamination of hematopoietic harvests: a review. J Hematother 1995; 4: 141-8.
22. Yeager AM, Wiley JM, Jones R, et al. Pharmacologic treatment of bone marrow to eliminate clonogenic tumour cells: laboratory and clinical studies. Bone Marrow Transplant 1987; 2 (Suppl 2): 34-42.
23. Jones R, Sharkis S, Colvin M. CFU-GM, CFU-S, predict repopulation ability of in vitro drug treated murine bone marrow. Exp Hematol 1986; 14: 438.
24. Kaizer H, Stuart RK, Brookmeyer R, et al. Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumour cells. Blood 1985; 65: 1504-10.
25. Douay L, Gorin NC, Laporte J-P, et al. ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows. Invest New Drugs 1984; 2: 187-90.
26. Rowley SD, Jones RJ, Piantadosi S, et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989; 74: 501-6.
27. Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in remission: decreased risk of relapse associated with marrow purging by mafosfamide. Blood 1990; 8: 1606-14.
28. Labopin M, Gorin NC, Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe; a retrospective study. Leukemia 1992; 6 (Suppl 4): 95.
29. Ritz J, Pesando JM, Notis-McConarty J, Lazaarus H, Schlossman S.F. A monoclonal antibody to the human acute lymphoblastic leukemia antigen. Nature 1980; 283: 585-7.
30. Ritz J, Sallan SE, Bast RC, et al. Autologous bone marrow transplantation in cALLA-positive acute lymphoblastic leukaemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 1982; ii: 60-3.
31. Bast RC, De Fabritiis P, Lipton J, et al. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985; 45: 499-503.
32. Winter JN, Marder RJ, Mankad B, Epstein AL. Heterogeneity among the non-Hodgkin's lymphomas. Cancer 1988; 61: 1082-90.
33. Bast RC, Montogomery RB, Haleem J, et al. Bone marrow purging with antibody and complement: an American review. Bone Marrow Transplant 1987; 2 (Suppl 2): 58-65.
34. Ball ED. In vitro purging of bone marrow for autologous marrow transplantation in acute myelogenous leukemia using myeloid-specific monoclonal antibodies. Bone Marrow Transplant 1988; 3: 387-92.
35. Janossy G, Campana D, Amlot P. Application of cytolytic monoclonal antibodies and complement in autologous bone marrow transplantation (BMT). Bone Marrow Transplant 1987; 2 (Suppl 2): 66-73.
36. Gee AP, Boyle MDP. Purging tumour cells from bone marrow by use of antibody and complement: a critical appraisal. J Natl Cancer Inst 1988; 80: 154-9.
37. Uhr J W. Immunotoxins: harnessing nature's poisons. J Immunol 1984; 133: i-x.
38. Vitetta ES, Uhr JW. Immunotoxins: redirecting nature's poisons. Cell 1985; 41: 653-4.
39. Olsnes S, Pihl A. Chimeric toxins. Pharmacol Ther 1982; 15: 335-81.
40. Blakey DC, Thorpe, PE. An overview of therapy with immunotoxins containing ricin or its A-chain. Antibody Immunoconjug Radiopharmaceut 1988; 1: 1-16.
41. Stong RC, Uckun F, Youle RJ, Kersey JH, Vallera DA. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood 1985; 66: 627-35.
42. Casellas P, Canat X, Fauser AA, et al. Optimal elimination of leukemia T cells from human bone marrow with T101-ricin A-chain immunotoxin. Blood 1985; 65: 289-97.
43. Uckun FM, Kersey JH, Vallera DA, et al. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723-33.
44. Fodstad Ø, Kvalheim G, Pihl A, Godal A, Funderud S. New indirect approach to the therapeutic use of immunotoxins. J Natl Cancer Inst 1988; 80: 439-43.
45. Bjorn MJ, Manger R, Sivam G, Morgan AC Jr, Torok-Storb B. Selective elimination of breast cancer cells from human bone marrow using an antibody-pseudomonas exotoxin A conjugate. Cancer Res 1990; 50: 5992-6.
46. Bjorn MJ, Groetsema G, Scalapino L. Antibody-pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitro. Cancer Res 1986; 46: 3262-7.
47. Myklebust AT, Godal A, Pharo A, Juell S, Fodstad O. Eradication of small cell lung cancer cells from human bone marrow with immunotoxins. Cancer Res 1993; 53: 3784-8.
48. Myklebust AT, Godal A, Juell S, Pharo A, Fodstad O. Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. Cancer Res 1994; 54: 209-14.
49. Treleaven JG, Gibson FM, Ugelstad J, et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; 1: 70-3.
50. Kvalheim G, Fodstad Ø, Pihl A, et al. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies. Cancer Res 1987; 47: 846-51.
51. Kvalheim G, Funderud S, Kvaloy S, et al. Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation. J Natl Cancer Inst 1988; 80: 1322-5.
52. Kvalheim G, Sorensen O, Fodstad Ø, et al. Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant 1988; 3: 31-41.
53. Wang MY, Kvalheim G, Kvaloy S, et al. An effective immunomagnetic method for bone marrow purging in T cell malignacies. Bone Marrow Transplant 1992; 9: 319-23.
54. Ogniben E, Hohaus S, Kvalheim G, Dorken H, Haas R. Successful autologous transplantation of immunomagnetic bead purged bone marrow in non-Hodgkin's lymphoma. Prog Clin Biol Res 1992; 377: 189-95.
55. Kvalheim G, Jakobsen E, Holte H, et al. Autologous bone marrow transplantation of non-Hodgkin's lymphoma patients with marrow purged with immunomagnetic beads. Adv Bone Marrow Purg Process 1994; 133-8.
56. Kiesel S, Haas R, Moldenhauer G, Kvalheim G, Pezzutto A, Dørken B. Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis. Leukemia Res 1987; 11: 1119-25.
57. Straka C, Dorken B, Kvalheim G. Polymerase chain reaction monitoring shows a high efficacy of clinical immunomagnetic purging in patients with centroblastic-centrocytic non-Hodgkin's lymphoma. Blood 1992; 15: 2688-90.
58. Deggerdal AH, Pettersen F, Kvalheim G, et al. Semiquantitative polymerase chain reaction for t(14;18) in follicular lymphomas: a colorimetric approach. Lab Invest 1995; 4: 1-7.
59. Sphall EJ, Jones RJ, Bearmenn SI, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
60. Dunbar CE, Cottier-Fox M, O'Shaughnessy J A. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-57.
61. Smeland EB, Funderud S, Kvalheim G, et al. Isolation and characterization of human hematopoietic progenitor cells: an efficient method for positive selection of CD34+ cells. Leukemia 1992; 6: 845-52.
62. Eaves CJ, Cashman JD, Eaves AC. Methodology of long-term culture of human hematopoietic cells. J Tissue Cult Methods 1991; 13: 55-61.
63. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Long-term marrow culture reveals chromosomal normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308: 1493-8.
64. Testa NG, Dexter M T. The biology of long-term bone marrow cultures and its application to bone marrow transplantation. Curr Opinion Oncol 1991; 3: 272-8.
65. Udomsakdi C, Eaves CJ, Swolin B, Reid Ds, Barnett MJ, Eaves AC. Rapid decline of chronic myeloid cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 1992; 89: 6192-6.
66. Brugger W, Helmfeld S, Berenson RJ, Mertelsman R, Kanz L. Reconstitution of hematopoieses after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995; 333: 283-7.
67. Ayash LJ, Elias A, Wheeler C, et al. Double dose intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.